Publications
Detailed Information
Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Eun, Hee Chul | - |
dc.contributor.author | Kwon, Oh Sang | - |
dc.contributor.author | Yeon, Je Ho | - |
dc.contributor.author | Shin, Hyo Seung | - |
dc.contributor.author | Ro, Byung In | - |
dc.contributor.author | Sim, Woo Young | - |
dc.contributor.author | Lee, Won-Soo | - |
dc.contributor.author | Hong, Seung Phil | - |
dc.contributor.author | Ji, Jae Hong | - |
dc.contributor.author | Park, Hwa Young | - |
dc.contributor.author | Lew, Bark Lynn | - |
dc.contributor.author | Cho, Han Kyong | - |
dc.contributor.author | Kim, Byung Yoon | - |
dc.date.accessioned | 2012-07-03T08:49:08Z | - |
dc.date.available | 2012-07-03T08:49:08Z | - |
dc.date.issued | 2010-08 | - |
dc.identifier.citation | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY; Vol.63(2); 252-258 | ko_KR |
dc.identifier.issn | 0190-9622 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78325 | - |
dc.description.abstract | Background: Dutasteride (Avodart) is a dual inhibitor of both type I and type II 5 alpha reductases, and thus inhibits conversion of testosterone to dihydrotestosterone, a key mediator of male pattern hair loss. Objectives: The aim of this randomized double-blind phase III study was to compare the efficacy, safety, and tolerability of dutasteride (0.5 mg) and placebo for 6 months of treatment in male patients with male pattern hair loss. Methods: A total of 153 men, 18 to 49 years old, were randomized to receive 0.5 mg of dutasteride or placebo daily for 6 months. Efficacy was evaluated by the change of hair counts, subject assessment, and photographic assessment by investigators and panels. Results: Mean change of hair counts from baseline to 6 months after treatment start was an increase of 12.2/cm(2) in dutasteride group and 4.7/cm(2) in placebo group and this difference was statistically significant (P = .0319). Dutasteride showed significantly higher efficacy than placebo group by subject self-assessment and by investigator and panel photographic assessment. There was no major difference in adverse events between two groups. Limitations: The study was limited to 6 months. Conclusions: This study clearly showed that 0.5 mg of dutasteride improved hair growth and was relatively well tolerated for the treatment of male pattern hair loss. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | MOSBY-ELSEVIER | ko_KR |
dc.subject | androgenetic alopecia | ko_KR |
dc.subject | dutasteride | ko_KR |
dc.subject | treatment | ko_KR |
dc.subject | male pattern hair loss | ko_KR |
dc.title | Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 은희철 | - |
dc.contributor.AlternativeAuthor | 권오상 | - |
dc.contributor.AlternativeAuthor | 연제호 | - |
dc.contributor.AlternativeAuthor | 신효승 | - |
dc.contributor.AlternativeAuthor | 김병윤 | - |
dc.contributor.AlternativeAuthor | 노병인 | - |
dc.contributor.AlternativeAuthor | 조한경 | - |
dc.contributor.AlternativeAuthor | 심우영 | - |
dc.contributor.AlternativeAuthor | 류박린 | - |
dc.contributor.AlternativeAuthor | 이원수 | - |
dc.contributor.AlternativeAuthor | 박화영 | - |
dc.contributor.AlternativeAuthor | 홍승필 | - |
dc.contributor.AlternativeAuthor | 지재홍 | - |
dc.identifier.doi | 10.1016/j.jaad.2009.09.018 | - |
dc.citation.journaltitle | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | - |
dc.description.citedreference | STOUGH D, 2007, J COSMET DERMATOL, V6, P9 | - |
dc.description.citedreference | Olsen EA, 2006, J AM ACAD DERMATOL, V55, P1014, DOI 10.1016/j.jaad.2006.05.007 | - |
dc.description.citedreference | Olsen EA, 2005, J AM ACAD DERMATOL, V52, P301, DOI 10.1016/j.jaad.2004.04.008 | - |
dc.description.citedreference | OLSZEWSKA M, 2005, J DRUGS DERMATOL, V4, P637 | - |
dc.description.citedreference | Debruyne F, 2004, EUR UROL, V46, P488, DOI 10.1016/j.eururo.2004.05.008 | - |
dc.description.citedreference | Clark RV, 2004, J CLIN ENDOCR METAB, V89, P2179, DOI 10.1210/jc.2003-030330 | - |
dc.description.citedreference | Roehrborn CG, 2004, UROLOGY, V63, P709, DOI 10.1016/j.urology.2004.01.001 | - |
dc.description.citedreference | Price VH, 1999, NEW ENGL J MED, V341, P964 | - |
dc.description.citedreference | Kaufman KD, 1998, J AM ACAD DERMATOL, V39, P578 | - |
dc.description.citedreference | Bramson HN, 1997, J PHARMACOL EXP THER, V282, P1496 | - |
dc.description.citedreference | Canfield D, 1996, DERMATOL CLIN, V14, P713 | - |
dc.description.citedreference | Courtois M, 1996, BRIT J DERMATOL, V134, P47 | - |
dc.description.citedreference | DALLOB AL, 1994, J CLIN ENDOCR METAB, V79, P703 | - |
dc.description.citedreference | RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25 | - |
dc.description.citedreference | OLSEN EA, 1994, DISORDERS HAIR GROWT, P257 | - |
dc.description.citedreference | THIGPEN AE, 1993, J CLIN INVEST, V92, P903 | - |
dc.description.citedreference | CASH TF, 1992, J AM ACAD DERMATOL, V26, P926 | - |
dc.description.citedreference | JENKINS EP, 1992, J CLIN INVEST, V89, P293 | - |
dc.description.citedreference | RANDALL VA, 1991, BRIT J DERMATOL, V124, P146 | - |
dc.description.citedreference | NORWOOD OT, 1975, SOUTHERN MED J, V68, P1359 | - |
dc.description.citedreference | IMPERATO.J, 1974, SCIENCE, V186, P1213 | - |
dc.description.citedreference | HAMILTON JB, 1951, ANN NY ACAD SCI, V53, P708 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.